A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

Study Overview

• Status: Not yet recruiting
• Conditions: Non-Small Cell Lung Cancer
• Intervention / Treatment: Drug: HS-20093 for Injection; Drug: Adebrelimab Injection

Detailed Description

This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

Eligible participants will be randomly assigned in a 1:1 ratio to the experimental arm (HS-20093 and adebrelimab) or the control arm (HS-20093 injection). Participants in the experimental arm will receive intravenous infusions of HS-20093 and adebrelimab until disease progression or other treatment discontinuation criteria are met. Participants in the control arm will receive HS-20093 injection until disease progression or other treatment discontinuation criteria are met. Efficacy and safety will be analyzed and evaluated in both arms following the protocol-specified follow-up procedures.

• Study Type: Interventional
• Enrollment (Estimated): 76
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥18 years at the time of informed consent form (ICF) signature, either sex.
2. Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent, and commitment to comply with all requirements specified in this clinical trial protocol.
3. Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
4. Presence of at least one measurable target lesion.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 1.
6. Minimum life expectancy >12 weeks.
7. Adequate organ function.
8. Absence of the following active infectious diseases: hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, tuberculosis, or syphilis.
9. Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.

Exclusion Criteria:

1. Prior pathological diagnosis of mixed non-small cell lung cancer or any transformed non-small cell lung cancer.

2. Prior or ongoing treatment with any of the following:

   1. Prior or current treatment targeting B7-H3;
   2. Prior or current treatment with topoisomerase I inhibitor agents, including antibody-drug conjugates with topoisomerase I inhibitor payloads, etc.;
   3. Prior treatment with docetaxel monotherapy or in combination with other agents.
3. Persistent adverse reactions caused by prior treatment.
4. Untreated brain metastases; uncontrolled brain metastases; presence of leptomeningeal or brainstem metastases; presence of spinal cord compression (identified by radiographic imaging, regardless of symptoms).
5. History of other primary malignancies.

6. Presence of any of the following abnormal cardiac findings:

   1. Evidence of currently clinically significant important arrhythmia or ECG abnormality;
   2. Presence of risk factors causing QT interval prolongation or arrhythmic events.
7. Severe, uncontrolled, or active cardiovascular or cerebrovascular disease.
8. Severe or poorly controlled hypertension.
9. Severe or poorly controlled diabetes mellitus.
10. Clinically significant bleeding symptoms or significant bleeding tendency.
11. Severe infection.
12. History of severe arterial or venous thromboembolic events.
13. Known or suspected interstitial pneumonitis, immune-mediated pneumonitis, or radiation pneumonitis.
14. Participants with active or history of autoimmune disease with potential for recurrence.
15. Prior occurrence of severe or life-threatening immune-mediated adverse events.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HS-20093 and adebrelimab	Drug: HS-20093 for Injection; The patient will be treated with HS-20093.; Other Names: GSK5764227; Risvutatug Rezetecan; Ris-Rez; Drug: Adebrelimab Injection; The patient will be treated with Adebrelimab
Active Comparator: HS-20093	Drug: HS-20093 for Injection; The patient will be treated with HS-20093.; Other Names: GSK5764227; Risvutatug Rezetecan; Ris-Rez

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	Objective Response Rate (ORR) assessed by investigator per RECIST v1.1	Up to 3 years
Progression-Free Survival (PFS)	2. Progression-Free Survival (PFS) assessed by investigator per RECIST v1.1	Approximately 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
duration of response (DoR)	DoR assessed by investigator per RECIST v1.1	Approximately 3 years
Overall survival (OS)	Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.	Approximately 5 years
Adverse event (AE) and serious adverse event (SAE)	Incidence and severity of AEs and SAEs	3 years
Changes from baseline in cardiac function [electrocardiogram (ECG)]	Changes from baseline in cardiac function [electrocardiogram (ECG)]. For all ECGs performed during the study, the following parameters will be recorded and assessed: cardiac rhythm, heart rate, PR interval, RR interval, QRS duration, and QT interval (with QTcF correction using Fridericia's formula). A global interpretation of the ECG tracing will also be provided.	3 years

Collaborators and Investigators

• Sponsor: Hansoh BioMedical R&D Company

Study record dates

Study Major Dates

• Study Start (Estimated): September 10, 2026
• Primary Completion (Estimated): March 30, 2028
• Study Completion (Estimated): September 30, 2029

Study Registration Dates

• First Submitted: August 13, 2026
• First Submitted That Met QC Criteria: September 11, 2026
• First Posted (Actual): September 17, 2026

Study Record Updates

• Last Update Posted (Actual): September 17, 2026
• Last Update Submitted That Met QC Criteria: September 11, 2026
• Last Verified: September 1, 2026

More Information

Terms related to this study

• Keywords: Non-Small Cell Lung Cancer; HS-20093; PD-L1 inhibitor; B7H3; Antibody-Drug Conjugates
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Therapeutics; Drug Administration Routes; Drug Therapy; Injections
• Other Study ID Numbers: HS-20093-209

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No